Oral exemestane 25 mg/day for 2–3 years of adjuvant therapy was generally more effective than 5 years of continuous adjuvant tamoxifen in the treatment of postmenopausal women with early-stage estrogen receptor-positive/unknown receptor status breast in a large well-designed [ citation needed ] trial. Preliminary data from the open-label TEAM trial comparing exemestane with tamoxifen indicated in 2009 that exemestane 25 mg/day is also effective in the primary adjuvant treatment of early-stage breast cancer in postmenopausal women. 
Dave, let me clear the air here on some of the confusion… I recommend the 1 vial cycle for someone who is either A. younger or either B. already has high levels of natural testosterone. Now, the typical middle aged male who already had declining levels of natural testosterone COULD go with 500 mg/wk for 10 wks. Recovery is recovery at that point and if you’re going to do it then I see nothing wrong with getting the most out of that first cycle. But what you have to realize is a male with a starting level of high average test levels can still yield the same benefits of someone who is middle range-low end of normal and uses 500mg/wk of test. In either case the person can still gain a solid 20 lbs of muscle from either 1 or 2 vials, the determining factor on this is what they were at to begin with
Cimetidine was first marketed in the United Kingdom in 1976, and in the . in August 1977; therefore, it took 12 years from initiation of the H 2 receptor antagonist program to commercialization. By 1979, Tagamet was being sold in more than 100 countries and became the top-selling prescription product in the ., Canada, and several other countries. In November 1997, the American Chemical Society and the Royal Society of Chemistry in the . jointly recognized the work as a milestone in drug discovery by designating it an International Historic Chemical Landmark during a ceremony at SmithKline Beecham's New Frontiers Science Park research facilities in Harlow, England.